Aarti Pharmalabs Ltd

Aarti Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Aarti Pharmalabs Ltd

₹ 471 0.33%
05 Dec 4:01 p.m.
aartipharmalabs.com BSE: 543748 NSE : AARTIPHARM
About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Key Points

Business Overview:[1]
Company is a Wholly Owned Subsidiary of Aarti Industries Limited. It develops Active Pharmaceutical Ingredients, New Chemical Entities, API intermediates, Regulatory Starting Materials, Basic Starting Materials, Key Building Blocks, and Xanthine Derivatives for use in clinical testing and commercial production. It also provides stability studies, scale-up and process optimisation, process validations, and commercial manufacturing.
Company has 6 manufacturing plants and 2 R&D centres.

Website BSE NSE
  • Market Cap ₹ 4,264 Cr.
  • Current Price ₹ 471
  • High / Low ₹ 485 / 235
  • Stock P/E 22.5
  • Book Value ₹ 183
  • Dividend Yield 0.00 %
  • ROCE 16.1 %
  • ROE 13.2 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company's working capital requirements have reduced from 174 days to 134 days

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023
460 457 531 472 485 458 440
385 371 441 385 405 373 352
Operating Profit 76 86 90 86 80 85 88
OPM % 16% 19% 17% 18% 16% 19% 20%
3 0 1 0 1 0 1
Interest 5 4 6 5 6 4 4
Depreciation 14 14 17 16 16 17 18
Profit before tax 59 68 69 65 59 64 67
Tax % 18% 24% 26% 27% 27% 26% 23%
49 52 51 48 43 47 52
EPS in Rs 5.26 4.73 5.20 5.72
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 TTM
0 1,200 1,945 1,855
0 993 1,603 1,516
Operating Profit 0 207 342 339
OPM % 17% 18% 18%
0 3 2 2
Interest 0 12 21 19
Depreciation 0 42 63 68
Profit before tax 0 155 261 255
Tax % 21% 26%
0 122 193 189
EPS in Rs 21.35 20.91
Dividend Payout % 0% 9%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 62%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 59%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 0 45 45
Reserves -0 1,386 1,513 1,612
0 341 215 207
0 312 457 449
Total Liabilities 0 2,040 2,231 2,313
0 782 926 1,006
CWIP 0 187 102 89
Investments 0 32 74 81
0 1,038 1,130 1,137
Total Assets 0 2,040 2,231 2,313

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023
0 -44 263
0 -139 -158
0 260 -163
Net Cash Flow 0 78 -58

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2021 Mar 2022 Mar 2023
Debtor Days 115 83
Inventory Days 272 216
Days Payable 123 125
Cash Conversion Cycle 264 174
Working Capital Days 214 134
ROCE % 19% 16%

Shareholding Pattern

Numbers in percentages

2 Recently
Mar 2023Jun 2023Sep 2023
45.98% 45.98% 46.30%
7.69% 7.43% 8.45%
13.68% 10.65% 10.51%
0.01% 0.01% 0.01%
32.64% 35.92% 34.73%
No. of Shareholders 2,76,6642,58,2392,26,286

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls